Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

eMedWorld

- PMLiVE

Pharma should not ignore India

It’s complicated, but multinational pharma cannot ignore a market with one billion plus people

China flag thumb

Diabetes management underestimated in Asia

Boehringer/Lilly survey highlights need to improve patient education in India, China, Japan and South Korea

- PMLiVE

Publicis Groupe adds to Indian portfolio

Comms group acquires Beehive Communications

- PMLiVE

Indian pharma market set for ‘significant’ growth

Forecast to be worth $56bn by 2020, despite regulatory uncertainty

Bristol-Myers Squibb (BMS) building

BMS says it defends Sprycel patent in India

Blocks attempts to issue compulsory license for leukaemia drug

Novartis building

Novartis said to want out of Indian vaccines venture

Reports in India claim the pharma company is pulling out of its deal with Panacea Biotec

- PMLiVE

Indian generics companies poised for branded push

Report predicts manufacturing innovation will be harnessed for new patented products

- PMLiVE

Roche loses Herceptin patents in India

Government says pharma company did not follow correct filing procedure

- PMLiVE

GSK loses patent on Tykerb in India

Cuts period of exclusivity by two years

- PMLiVE

Intellectual property threats in the BRIC markets

Compulsory licensing and other legal concerns for pharma in emerging markets

Evotec shutters chemistry operations to exit India

Thane facility to close with loss of 120 jobs

- PMLiVE

The rise of chronic disease in BRIC markets

Changing disease patterns in the BRIC nations are providing new opportunities for growth

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links